Northwest & Ethical Investments L.P. Has $3.10 Million Holdings in Illumina, Inc. $ILMN

Key Points

• Northwest & Ethical Investments L.P. has reduced its holdings in Illumina, Inc. by 35.9%, owning 39,017 shares worth approximately $3.1 million after selling 21,837 shares in Q1.
• Several hedge funds have adjusted their positions in Illumina recently, with Mariner LLC increasing its stake by 13.5% and Jump Financial LLC boosting its position by an impressive 260.0%.
• Illumina received mixed ratings from analysts, with recent downgrades from Citigroup and Daiwa America, while Evercore ISI raised its price target from $116.00 to $128.00.

Northwest & Ethical Investments L.P. lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 35.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,017 shares of the life sciences company's stock after selling 21,837 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in Illumina were worth $3,096,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ILMN. Brown Advisory Inc. lifted its stake in shares of Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after acquiring an additional 1,909,118 shares during the period. Assenagon Asset Management S.A. grew its stake in Illumina by 2,057.5% in the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after acquiring an additional 879,533 shares during the period. Vanguard Group Inc. grew its stake in Illumina by 3.5% in the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after acquiring an additional 558,243 shares during the period. Pacer Advisors Inc. grew its stake in Illumina by 2,292.9% in the first quarter. Pacer Advisors Inc. now owns 565,680 shares of the life sciences company's stock valued at $44,881,000 after acquiring an additional 542,040 shares during the period. Finally, Spyglass Capital Management LLC acquired a new position in Illumina in the fourth quarter valued at about $71,855,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research analyst reports. Robert W. Baird boosted their target price on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. Barclays boosted their target price on Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research note on Friday, August 1st. Royal Bank Of Canada boosted their target price on Illumina from $118.00 to $126.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. Scotiabank downgraded Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price on the stock. in a research report on Friday, July 11th. Finally, Canaccord Genuity Group lifted their price target on shares of Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research report on Friday, August 1st. Seven equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $124.58.

Illumina Price Performance

Illumina stock traded up $2.51 during mid-day trading on Friday, reaching $101.80. The company had a trading volume of 1,964,101 shares, compared to its average volume of 1,883,205. The business has a fifty day simple moving average of $98.18 and a 200 day simple moving average of $89.13. The company has a market cap of $15.65 billion, a P/E ratio of 12.89, a P/E/G ratio of 2.23 and a beta of 1.37. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company's revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.